

Claims

- [1] 1. A use of a soluble glucan oligomer derived from yeast variant strain IS2 (KCTC 0959BP) for the preparation of therapeutic agent for treatment and prevention of the diseases caused by the infection of influenza virus and transmissible gastroenteritis coronavirus in human and mammal.
- [2] 2. The use according to claim 1 wherein said influenza virus is influenza virus A, B, C or swine influenza virus.
- [3] 3. The use according to claim 1 wherein said diseases infected by influenza virus is influenza, common cold, laryngopharyngitis, bronchitis or pneumonia.
- [4] 4. The use according to claim 1 wherein said disease infected by transmissible gastroenteritis coronavirus is common cold, severe acute respiratory disease, porcine epidemic diarrhea (PED) or transmissible gastro enteritis (TGE).
- [5] 5. The use according to claim 1 wherein said mammal is human and domestic animals.
- [6] 6. A pharmaceutical composition comprising soluble glucan oligomer derived from the cell wall of yeast variant strain (KTCT 0959BP) obtained by treating insoluble beta-glucan with enzyme, for treating and preventing the diseases caused by the infection of influenza virus and transmissible gastroenteritis coronavirus in human and mammal.
- [7] 7. A health care food comprising the soluble glucan oligomer derived from yeast variant strain IS2 (KCTC 0959BP) as an active ingredient, together with a sitologically acceptable additive for the prevention and improvement of mammal's diseases caused by the infection of influenza virus and transmissible gastroenteritis coronavirus.